141 related articles for article (PubMed ID: 38329225)
1. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Delzenne G; Boileau M; Jamme P; Farchi O; Mortier L
Melanoma Res; 2024 Apr; 34(2):182-185. PubMed ID: 38329225
[TBL] [Abstract][Full Text] [Related]
2. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
4. Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.
Boileau M; Descarpentries C; Delzenne G; Trentesaux V; Greliak A; Jamme P; Marchetti P; Mortier L
Melanoma Res; 2023 Jun; 33(3):247-251. PubMed ID: 36866640
[TBL] [Abstract][Full Text] [Related]
5. Testing for
Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
[TBL] [Abstract][Full Text] [Related]
6. SKAP2-BRAF fusion and response to an MEK inhibitor in a patient with metastatic melanoma resistant to immunotherapy.
Chew SM; Lucas M; Brady M; Kelly CM
BMJ Case Rep; 2021 Jun; 14(6):. PubMed ID: 34167970
[TBL] [Abstract][Full Text] [Related]
7. Identification of fusions with potential clinical significance in melanoma.
Moran JMT; Le LP; Nardi V; Golas J; Farahani AA; Signorelli S; Onozato ML; Foreman RK; Duncan LM; Lawrence DP; Lennerz JK; Dias-Santagata D; Hoang MP
Mod Pathol; 2022 Dec; 35(12):1837-1847. PubMed ID: 35871080
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
Pires da Silva I; Zakria D; Ahmed T; Trojanello C; Dimitriou F; Allayous C; Gerard C; Zimmer L; Lo S; Michielin O; Lebbe C; Mangana J; Ascierto PA; Johnson DB; Carlino M; Menzies A; Long G
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798536
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?
Moreno-Ramírez D; Fernández-Orland A; Ferrándiz L
Actas Dermosifiliogr; 2024 Jan; 115(1):48-55. PubMed ID: 37321549
[TBL] [Abstract][Full Text] [Related]
12. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
13. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.
McEvoy CR; Xu H; Smith K; Etemadmoghadam D; San Leong H; Choong DY; Byrne DJ; Iravani A; Beck S; Mileshkin L; Tothill RW; Bowtell DD; Bates BM; Nastevski V; Browning J; Bell AH; Khoo C; Desai J; Fellowes AP; Fox SB; Prall OW
J Clin Invest; 2019 May; 129(5):1940-1945. PubMed ID: 30835257
[TBL] [Abstract][Full Text] [Related]
14. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
15. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Lodde GC; Jansen P; Möller I; Sucker A; Hassel JC; Forschner A; Eckardt J; Meier F; Reinhardt L; Kähler KC; Ziemer M; Schlaak M; Rahimi F; Schatton K; Meiss F; Gutzmer R; Pföhler C; Terheyden P; Schilling B; Sachse M; Heppt MV; Sindrilaru A; Leiter U; Zaremba A; Thielmann CM; Ugurel S; Zimmer L; Hadaschik E; Bechrakis NE; Schadendorf D; Westekemper H; Livingstone E; Griewank KG;
Eur J Cancer; 2022 May; 166():60-72. PubMed ID: 35279471
[TBL] [Abstract][Full Text] [Related]
16. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A; Lawrence D; Atkinson V; Agarwal S; Miller WH; Carlino MS; Fisher R; Long GV; Hodi FS; Tsoi J; Grasso CS; Mookerjee B; Zhao Q; Ghori R; Moreno BH; Ibrahim N; Hamid O
Nat Med; 2019 Jun; 25(6):936-940. PubMed ID: 31171879
[TBL] [Abstract][Full Text] [Related]
17. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
18. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Palanisamy N; Ateeq B; Kalyana-Sundaram S; Pflueger D; Ramnarayanan K; Shankar S; Han B; Cao Q; Cao X; Suleman K; Kumar-Sinha C; Dhanasekaran SM; Chen YB; Esgueva R; Banerjee S; LaFargue CJ; Siddiqui J; Demichelis F; Moeller P; Bismar TA; Kuefer R; Fullen DR; Johnson TM; Greenson JK; Giordano TJ; Tan P; Tomlins SA; Varambally S; Rubin MA; Maher CA; Chinnaiyan AM
Nat Med; 2010 Jul; 16(7):793-8. PubMed ID: 20526349
[TBL] [Abstract][Full Text] [Related]
19. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Rasco DW; Medina T; Corrie P; Pavlick AC; Middleton MR; Lorigan P; Hebert C; Plummer R; Larkin J; Agarwala SS; Daud AI; Qiu J; Bozon V; Kneissl M; Barry E; Olszanski AJ
Cancer Chemother Pharmacol; 2023 Jul; 92(1):15-28. PubMed ID: 37219686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
